https://seekingalpha.com/news/4051439-corcept-therapeutics-plunges-after-loss-in-patent-battle-with-with-teva?source=feed_sector_healthcare
Jan 01, 2024 - Corcept Therapeutics (CORT) tumbles 38% in after-hours trading following a patent trial loss to Teva (TEVA) over its Cushing's syndrome drug, Korlym.
0
sa:-1248045273813464132
0
https://www.zacks.com/stock/news/2204522/corcept-cort-falls-on-loss-of-korlym-patent-lawsuit-to-teva?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2204522
Jan 02, 2024 - The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
zc:-1703106103405717870
0
https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?source=feed_tag_israel
Jan 23, 2024 - Jefferies upgrades Teva Pharmaceutical (TEVA) to Buy from Hold ahead of the company's 2024 outlook citing multiple tailwinds to its business. Read more here.
0
sa:6350376612566908781
0
https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216435
Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
zc:-2075254192096239650
0
https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html
Jan 28, 2024 - Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
0
cnbc:5367017634271496105
0
https://www.zacks.com/stock/news/2218858/teva-pharmaceutical-industries-ltd-teva-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2218858
Jan 31, 2024 - Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:-3864595263157246483
0
https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel
Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.
0
sa:2780130738788668401
0
https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel
Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
0
sa:2521424083335389399
0
https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel
Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
0
sa:735848729095779519
0
https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel
Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
0
sa:-4150960373662229940
0